Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence

2015; BMJ; Volume: 3; Issue: S2 Linguagem: Inglês

10.1186/2051-1426-3-s2-p166

ISSN

2051-1426

Autores

Jeffrey S. Weber, Jean‐Jacques Grob, Kim Margolin, Paolo A. Ascierto, Mario Sznol, Patrick A. Ott, Chantal Lejeune, Veerle de Pril, Mary Ruisi, F. Stephen Hodi,

Tópico(s)

Colorectal Cancer Treatments and Studies

Resumo

Meeting abstracts There is currently no consensus on the standard of care for pts with completely resected stage IIIB/C or stage IV MEL with no evidence of disease (NED) who are at high risk for recurrence. NIVO, a PD-1 immune checkpoint inhibitor, is approved in the United States, Europe, and

Referência(s)